Health Canada
Government regulatorGovernment of Canada federal regulator and public-health department · Canada
Visit the source site · Audited 2026-10-14
Who pays for it
Health Canada says most funding comes from Parliamentary appropriations; it reported CAD$317.4 million in fee revenue in FY2024–25, including CAD$98.3 million in human-drug submission examination fees.
Status: Labeled
Health Canada has a published scientific-integrity policy, but it is a federal regulator and receives cost-recovery fees from regulated companies. Its notices are labeled as regulatory monitoring and checked against an independent lactation evidence source.
How SafeMomma uses it
We use its dated regulatory notices as monitoring information, not as stand-alone reviews of drug transfer into milk.
The audit
- Who controls it
- Health Canada is a federal regulator and public-health department. Its joint scientific-integrity policy applies to employees who produce, manage or communicate science and states that scientific products are to be free from political, commercial, client and stakeholder interference.
- Money
- Most funding comes from annual Parliamentary appropriations. Health Canada reported CAD$317.4 million in FY2024–25 fees across fee authorities, including CAD$98.3 million for human-drug submission examinations; a budget for the sampled notice was not verified.
- Conflict rules
- The 2019 policy requires real, potential or apparent conflicts to be recognized, reported and managed. The sampled InfoWatch notice does not include article-author financial disclosures.
- Method
- The August 2023 InfoWatch domperidone notice describes nine case reports, four Canadian and five international, notes limited case information and says the Department would work with manufacturers on monograph language. This is post-market monitoring, not a systematic review of drug transfer into milk.
- Dates on its pages
- The sampled InfoWatch item is dated August 2023; notices have different publication and update dates, and no portfolio-wide median age was verified.
- Political exposure
- The integrity policy requires drafts to go to managers before formal publication and requires management approval for publication commenting on or recommending federal policy. No politically ordered change to the sampled lactation content was identified.
- Money exposure
- Companies pay regulatory fees for product submissions and licences, which are cost-recovery arrangements rather than voluntary sponsorship. The fee report does not tie revenues to the InfoWatch notice or identify company influence on it.
- Track record
- The sampled notice reports case counts, limitations and planned monograph follow-up, and concerns psychiatric withdrawal reports during off-label use to stimulate lactation. No source-specific correction or politically pressured content change was identified in the reviewed materials; none of b1-b5 supplied a separate Health Canada test finding.
Where this comes from
Incentive exposure describes pressure from money or politics, not whether the source is right. Funding alone does not show influence.